Testosterone therapy in women: Myths and misconceptions

Maturitas

Volumn 74, Issue 3, 2013, Pages 230-234

  Glaser, Rebecca ^a,b   Dimitrakakis, Constantine ^c,d  

^a Millennium Wellness Center   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Implants; Misconceptions; Safety; Testosterone; Therapy; Women

Indexed keywords

MOOD STABILIZER; TESTOSTERONE; BLOOD CLOTTING FACTOR; CARDIOTONIC AGENT;

AGGRESSION; ANDROGEN THERAPY; ANXIETY; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; DRUG SAFETY; HAIR GROWTH; HEART PROTECTION; HOARSENESS; HUMAN; IRRITABILITY; LIBIDO; LITERATURE; LIVER INJURY; REVIEW; SCALP HAIR; VOICE CHANGE; AFFECT; DRUG EFFECTS; FEMALE; GROWTH, DEVELOPMENT AND AGING; HAIR; HEALTH STATUS; HORMONE SUBSTITUTION; LIVER; MENTAL HEALTH; PROCEDURES; VOICE;

AFFECT; BLOOD COAGULATION FACTORS; CARDIOTONIC AGENTS; FEMALE; HAIR; HEALTH STATUS; HORMONE REPLACEMENT THERAPY; HUMANS; LIVER; MENTAL HEALTH; TESTOSTERONE; VOICE;

EID: 84875463109     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2013.01.003     Document Type: Review

References (44)

1. Dimitrakakis C, Zhou J, Bondy CA. Androgens and mammary growth and neoplasia. Fertility and Sterility 2002;77:26-33.
2. Salmon UJ. Effect of testosterone propionate upon gonadotropic hormone excretion and vaginal smears of human female castrate. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, NY) 1937;3:488-91.
3. Takeda H, Chodak G, Mutchnik S, Nakamoto T, Chang C. Immunohistochemical localization of androgen receptors with mono-and polyclonal antibodies to androgen receptor. Journal of Endocrinology 1990;126:17-25.
4. Wilson CM, McPhaul MJ. A and B forms of the androgen receptor are expressed in a variety of human tissues. Molecular and Cellular Endocrinology 1996;120:51-7.
5. Glaser R, York AE, Dimitrakakis C. Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS). Maturitas 2011;68:355-61.
6. Maclaran K, Panay N. The safety of postmenopausal testosterone therapy. Womens Health 2012;8:263-75.
7. Davey DA. Androgens in women before and after the menopause and post bilateral oophorectomy: clinical effects and indications for testosterone therapy. Womens Health 2012;8:437-46.
8. Loeser AA. Male hormone in gynaecology and obstetrics and in cancer of the female breast. Obstetrical & Gynecological Survey 1948;3:363-81.
9. Glaser R, Kalantaridou S, Dimitrakakis C. Testosterone implants in women: pharmacological dosing for a physiologic effect. Maturitas 2013;74:179-84.
10. Glaser RL, Dimitrakakis C, Messenger AG. Improvement in scalp hair growth in androgen-deficient women treated with testosterone: a questionnaire study. British Journal of Dermatology 2012;166:274-8.
11. Brunskill PJ. The effects of fetal exposure to danazol. BJOG: An International Journal of Obstetrics and Gynaecology 1992;99:212-5.
12. Tarttelin MF. Early prenatal treatment of ewes with testosterone completely masculinises external genitalia of female offspring but has no effects on early body weight changes. Acta Endocrinologica 1986;113:153-60.
13. Wolf CJ, Hotchkiss A, Ostby JS, LeBlanc GA, Gray LE. Effects of prenatal testosterone propionate on the sexual development of male and female rats: a dose-response study. Toxicological Sciences 2002;65:71-86.
14. Hotchkiss AK, Lambright CS, Ostby JS, Parks-Saldutti L, Vandenbergh JG, Gray LE. Prenatal testosterone exposure permanently masculinizes anogenital distance, nipple development, and reproductive tract morphology in female Sprague- Dawley rats. Toxicological Sciences 2007;96:335-45.
15. Mizuno M, Lobotsky J, Lloyd CW, Kobayashi T, Murasawa Y. Plasma androstenedione and testosterone during pregnancy and in the newborn. Journal of Clinical Endocrinology & Metabolism 1968;28:1133-42.
16. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clinical Pharmacokinetics 2004;43:487-514.
17. Schwartz SR, Cohen SM, Dailey SH, et al. Clinical practice guideline: hoarseness (dysphonia). Otolaryngology-Head and Neck Surgery 2009;141:S1-31.
18. Pattie MA, Murdoch BE, Theodoros D, Forbes K. Voice changes in women treated for endometriosis and related conditions: the need for comprehensive vocal assessment. Journal of Voice 1998;12:366-71.
19. Nordenskjold F, Fex S. Vocal effects of danazol therapy. Acta Obstetricia et Gynecologica Scandinavica 1984;63:131-2.
20. Arias-Santiago S, Gutierrez-Salmeron MT, Castellote-Caballero L, Buendia- Eisman A, Naranjo-Sintes R. Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study. Journal of the American Academy of Dermatology 2010;63:420-9.
21. Matilainen V, Laakso M, Hirsso P, Koskela P, Rajala U, Keinanen-Kiukaanniemi S. Hair loss, insulin resistance, and heredity in middle-aged women. A populationbased study. European Journal of Cardiovascular Risk 2003;10:227-31.
22. Tomlinson JW, Finney J, Hughes BA, Hughes SV, Stewart PM. Reduced glucocorticoid production rate, decreased 5-αreductase activity, and adipose tissue insulin sensitization after weight loss. Diabetes 2008;57:1536-43.
23. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009;207:318.
24. Moller J, Einfeldt H. Testosterone treatment of cardiovascular diseases: principles and clinical experience. Springer-Verlag; 1984. pp. 1-83.
25. Rosano GMC, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999;99:1666-70.
26. Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis SR. Evidence that parenteral testosterone therapy may improve endothelium-dependent and-independent vasodilation in postmenopausal women already receiving estrogen. Journal of Clinical Endocrinology & Metabolism 2001;86:158-61.
27. Malkin CJ, Pugh PJ, West JN, van Beek EJR, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. European Heart Journal 2006;27:57-64.
28. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96:1821-5.
29. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. Journal of Clinical Endocrinology & Metabolism 2008;93:68-75.
30. Iellamo F, Volterrani M, Caminiti G, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. Journal of the American College of Cardiology 2010;56:1310-6.
31. Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. Journal of Clinical Endocrinology & Metabolism 1996;81:4113-21.
32. O'Connor DB, Archer J, Wu FCW. Effects of testosterone on mood, aggression, and sexual behavior in young men: a double-blind, placebo-controlled, cross-over study. Journal of Clinical Endocrinology & Metabolism 2004;89: 2837-45.
33. Trainor BC, Kyomen HH, Marler CA. Estrogenic encounters: how interactions between aromatase and the environment modulate aggression. Frontiers in Neuroendocrinology 2006;27:170-9.
34. Giammanco M, Tabacchi G, Giammanco S, Di Majo D, La Guardia M. Testosterone and aggressiveness. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 2005;11:RA136.
35. Hickey TE, Robinson JLL, Carroll JS, Tilley WD. Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor oncogene? Molecular Endocrinology 2012;26:1252-67.
36. Eigeliene N, Elo T, Linhala M, Hurme S, Erkkola R, Harkonen P. Androgens inhibit the stimulatory action of 17-estradiol on normal human breast tissue in explant cultures. Journal of Clinical Endocrinology & Metabolism 2012;97:E1116-27.
37. Hofling M, Hirschberg AL, Skoog L, Tani E, Hagerstrom T, von Schoultz B. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 2007;14:183-90.
38. Dimitrakakis C, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003;10:292-8.
39. Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004;11:531-5.
40. Glaser R. Subcutaneous testosterone-anastrozole implant therapy in breast cancer survivors. In: American society of clinical oncology breast cancer symposium. 2010. D:221.
41. A221102, Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias.
42. GambrellJr RD, Natrajan PK. Moderate dosage estrogen-androgen therapy improves continuation rates in postmenopausal women: impact of the WHI reports. Climacteric 2006;9:224-33.
43. Traish AM, Gooren LJ. Safety of physiological testosterone therapy in women: lessons from female to male transsexuals (FMT) treated with pharmacological testosterone therapy. The Journal of Sexual Medicine 2010;7:3758-64.
44. Van Staa TP, Sprafka JM. Study of adverse outcomes in women using testosterone therapy. Maturitas 2009;62:76-80.